The Food and Drug Administration on Monday is launching an agencywide generative AI tool aimed at helping scientific reviewers, investigators and others streamline their work, according to details shared with Axios.
Why it matters: The model, dubbed "Elsa," is being rolled out weeks ahead of schedule and is designed to help with tasks such as summarizing adverse events to support drug safety profiles, and to generate code for databases.
Sanofi agreed to acquire Blueprint Medicines, a Cambridge, Mass.-based biotech focused on rare immunology diseases, for $9.1 billion in cash and up to $400 million in earnouts.
Why it matters: This is Sanofi's third big buy in 2025, following Dren Bo and Vigil Neuroscience, as it tries to build up a portfolio that's become too reliant on its Dupixent anti-inflammatory drug.
Robert F. Kennedy Jr.'s tenure as the nation's top health official is becoming increasingly known for abrupt policy pronouncements based on limited or sketchy evidence that perplex health care providers, industries and patients.
Why it matters: While Kennedy has branded himself as a change agent bringing "radical transparency" to a bloated federal bureaucracy and promoting "gold standard" science, the results have at times been chaotic, even exposingrifts between President Trump's circle and Kennedy's own base.
The Department of Health and Human Services' watchdog identified more than $16 billion in overpayments, fraudulent billings and possible cost savings in health programs over a half year spanning the Biden and Trump administrations, including more than $3.5 billion to be returned to the government.
Why it matters: The semiannual summary, first shared publicly to Axios, comes as the Trump administration says it's prioritizing government efficiency and rooting out waste, fraud and abuse.
